Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTT3P91)

• DTT Name: Synaptic vesicle glycoprotein 2A (SV2A)
• Synonyms: SV2A
• Gene Name: SV2A
• DTT Type: Successful target; [1]
• BioChemical Class: Major facilitator superfamily
• UniProt ID: SV2A_HUMAN
• TTD ID: T73676
• Sequence:
  MEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFEEEDDDDDFPA
  PSDGYYRGEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPRAESGGKGERMADGAPLA
  GVRGGLSDGEGPPGGRGEAQRRKEREELAQQYEAILRECGHGRFQWTLYFVLGLALMADG
  VEVFVVGFVLPSAEKDMCLSDSNKGMLGLIVYLGMMVGAFLWGGLADRLGRRQCLLISLS
  VNSVFAFFSSFVQGYGTFLFCRLLSGVGIGGSIPIVFSYFSEFLAQEKRGEHLSWLCMFW
  MIGGVYAAAMAWAIIPHYGWSFQMGSAYQFHSWRVFVLVCAFPSVFAIGALTTQPESPRF
  FLENGKHDEAWMVLKQVHDTNMRAKGHPERVFSVTHIKTIHQEDELIEIQSDTGTWYQRW
  GVRALSLGGQVWGNFLSCFGPEYRRITLMMMGVWFTMSFSYYGLTVWFPDMIRHLQAVDY
  ASRTKVFPGERVEHVTFNFTLENQIHRGGQYFNDKFIGLRLKSVSFEDSLFEECYFEDVT
  SSNTFFRNCTFINTVFYNTDLFEYKFVNSRLINSTFLHNKEGCPLDVTGTGEGAYMVYFV
  SFLGTLAVLPGNIVSALLMDKIGRLRMLAGSSVMSCVSCFFLSFGNSESAMIALLCLFGG
  VSIASWNALDVLTVELYPSDKRTTAFGFLNALCKLAAVLGISIFTSFVGITKAAPILFAS
  AALALGSSLALKLPETRGQVLQ
• Function: Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles.
• KEGG Pathway: ECM-receptor interaction (hsa04512)
• Reactome Pathway:
  Toxicity of botulinum toxin type A (botA) (R-HSA-5250968)
  Toxicity of botulinum toxin type F (botF) (R-HSA-5250981)
  Toxicity of botulinum toxin type E (botE) (R-HSA-5250992)
  Toxicity of botulinum toxin type D (botD) (R-HSA-5250955)

Molecular Interaction Atlas (MIA) of This DTT

2 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brivaracetam	DMSEPK8	Complex partial seizure	8A68.0	Approved	[1]
Levetiracetam	DMTGDN8	Epilepsy	8A60-8A68	Approved	[2]

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Padsevonil	DMRZ1F2	Epilepsy	8A60-8A68	Phase 2/3	[3]

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Seletracetam	DM3IJMN	Epilepsy	8A60-8A68	Discontinued in Phase 3	[4]

References

• [1] Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925-39.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20.
• [4] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.